by divibasicbldev | Jun 11, 2025 | Press Releases
Dr. James Lee of the Francis Crick Institute will help guide development of PAS-004 for ETS2-driven diseases such as inflammatory bowel disease (IBD)MIAMI, June 11, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the...
by divibasicbldev | Jun 2, 2025 | Press Releases
— PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid tumors — — One patient in cohort 4A (15mg capsule) with stage 4 BRAF-mutated melanoma, who had progressed after two prior...
by divibasicbldev | May 20, 2025 | Press Releases
— Demonstrates PAS-004’s potential as a differentiated MEK inhibitor for immune-mediated inflammatory diseases such as IBD and ankylosing spondylitis – — Positions PAS-004 for potential expansion beyond MAPK pathway driven tumors into...
by divibasicbldev | May 14, 2025 | Press Releases
— First patient expected to be dosed during Q2 2025 —- Trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in both plexiform neurofibromas and cutaneous neurofibromas —- Starting dose of 4mg tablet...
by divibasicbldev | May 7, 2025 | Press Releases
Additional Gross Proceeds of Approximately $1.3 Million Received Upon Exercise of Certain Warrants Issued in the Public OfferingMIAMI, May 07, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics, Corp. (“Pasithea,” or the “Company”) (Nasdaq:...
